Digestive Diseases and Sciences

, Volume 57, Issue 4, pp 1013–1019 | Cite as

Durability of Infliximab Dose Intensification in Crohn’s Disease

  • Kirk K. LinEmail author
  • Fernando Velayos
  • Elena Fisher
  • Jonathan P. Terdiman
Original Article



Dose intensification is a common approach to treat Crohn’s disease (CD) patients who lose response to infliximab maintenance therapy. Few studies have reported upon its long-term efficacy or predictors of response.


The goal of this study is to investigate durability and predictors of response to dose intensification—including method of dose intensification, combination immunomodulator therapy, and premedication with intravenous hydrocortisone.


We performed a retrospective study of dose-intensified CD patients at our institution. Dose intensification was defined as an increase in dose from 5 to 10 mg/kg, an increase in frequency of infusions from every 8 weeks to every 6 weeks or less, or both an increase in dose and frequency.


Thirty CD patients (mean age, 39.9 years) met study criteria and underwent dose intensification. Ten (33.3%) patients remained on dose intensification at the end of our study or returned to their former infliximab dose or schedule (median follow-up, 41 months). Fourteen patients (46.7%) eventually lost response to dose intensification, but dose intensification extended infliximab therapy by a median duration of 9 months. Six patients (20%) didn’t respond to dose intensification. Neither method of dose intensification, combination immunomodulator therapy, nor premedication with intravenous hydrocortisone predicted initial or durable response to dose intensification. However, analysis of predictors was limited by the small sample size of our study.


The majority of CD patients respond to dose intensification, and a substantial portion will experience durable response such that infliximab therapy is successfully extended by one or more years.


Infliximab Dose intensification Response Durability 


Conflict of interest

The authors have no commercial, proprietary, or financial interest in the products described in this article.


  1. 1.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.PubMedCrossRefGoogle Scholar
  2. 2.
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58:492–500.PubMedCrossRefGoogle Scholar
  3. 3.
    Moss AC, Fernandez-Becker N, Kim KJ, et al. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s disease. Aliment Pharmacol Ther. 2008;28:221–227.PubMedCrossRefGoogle Scholar
  4. 4.
    Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn’s disease treatment with infliximab. Dig Dis Sci. 2008;53:1033–1041.PubMedCrossRefGoogle Scholar
  5. 5.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.PubMedCrossRefGoogle Scholar
  6. 6.
    Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.PubMedCrossRefGoogle Scholar
  7. 7.
    Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005;23:469–474.PubMedGoogle Scholar
  8. 8.
    Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:1233–1238.PubMedCrossRefGoogle Scholar
  9. 9.
    Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31–36.PubMedGoogle Scholar
  10. 10.
    D’Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biologic therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2010; doi:  10.1038/ajg.2010.392.
  11. 11.
    Chaparro M, Martinez MP, Van-Domselaar M, et al. Intensification of infliximab (IFX) therapy in 100 patients with Crohn’s disease. Gastroenterology. 2008;134:A664.Google Scholar
  12. 12.
    Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn’s disease. Inflamm Bowel Dis. 2007;13:1093–1099.PubMedCrossRefGoogle Scholar
  13. 13.
    Magro F, Bastos R, Marques M, et al. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis. 2008;14:432–434.PubMedCrossRefGoogle Scholar
  14. 14.
    Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther. 2011;33:349–357.PubMedCrossRefGoogle Scholar
  15. 15.
    Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1248–1254.PubMedCrossRefGoogle Scholar
  16. 16.
    Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523–529.PubMedGoogle Scholar
  17. 17.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608.PubMedCrossRefGoogle Scholar
  18. 18.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124:917–924.PubMedCrossRefGoogle Scholar
  19. 19.
    Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol. 2000;95:1955–1960.PubMedCrossRefGoogle Scholar
  20. 20.
    Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641–6647.PubMedCrossRefGoogle Scholar
  21. 21.
    Kaplan GG, Hur C, Korsenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509–1520.PubMedCrossRefGoogle Scholar
  22. 22.
    Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn’s disease. Ther Adv Gastroenterol. 2010;3:179–189.CrossRefGoogle Scholar
  23. 23.
    Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–1139.PubMedCrossRefGoogle Scholar
  24. 24.
    Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101.PubMedCrossRefGoogle Scholar
  25. 25.
    Madhusudan G, Hans H, Drossman D. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7:48–53.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Kirk K. Lin
    • 1
    • 2
    Email author
  • Fernando Velayos
    • 1
  • Elena Fisher
    • 1
  • Jonathan P. Terdiman
    • 1
  1. 1.Division of Gastroenterology, Department of Internal MedicineUniversity of California at San FranciscoSan FranciscoUSA
  2. 2.Center for Colitis and Crohn’s DiseaseUniversity of California at San FranciscoSan FranciscoUSA

Personalised recommendations